(Reuters) – Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its experimental drug for type 1 and 2 diabetes, sending its shares up 3.2%.
The drug, BMF-219, is being tested in an early-to-mid stage study for type 2 diabetes and a mid-stage study for type 1 diabetes.
The hold was placed by the regulator in June due to liver toxicity concerns.
“None of the elevated lab values translated to confirmed serious liver injury or liver impairment,” said CEO Thomas Butler.
(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)
Comments